Key Points
- Gilead Sciences insider Johanna Mercier sold 28,000 shares on May 15 at an average price of $131.29, totaling about $3.68 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and her ownership fell by 18.21%.
- The company reported solid quarterly results on May 7, with EPS of $2.03 beating estimates and revenue of $6.96 billion slightly above forecasts. Revenue rose 4.4% year over year, and the firm’s return on equity was 48.19%.
- Gilead announced a quarterly dividend of $0.82 per share, payable June 29, for an annualized yield of about 2.5%. Analysts currently rate the stock a Moderate Buy with a consensus price target of $157.04.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the company's stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer owned 173,191 shares in the company, valued at $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gilead Sciences Stock Performance
Shares of GILD stock opened at $129.67 on Tuesday. The business's 50 day simple moving average is $137.46 and its 200 day simple moving average is $133.40. Gilead Sciences, Inc. has a one year low of $102.84 and a one year high of $157.29. The stock has a market capitalization of $160.99 billion, a PE ratio of 17.67 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to analysts' expectations of $6.91 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The firm's revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences's dividend payout ratio is presently 44.69%.
Hedge Funds Weigh In On Gilead Sciences
A number of large investors have recently modified their holdings of GILD. Vanguard Group Inc. grew its position in Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. State Street Corp grew its position in Gilead Sciences by 1.9% in the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the period. Price T Rowe Associates Inc. MD grew its position in Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock valued at $3,399,734,000 after purchasing an additional 1,195,269 shares during the period. Bank of America Corp DE grew its position in Gilead Sciences by 15.2% in the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock valued at $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Norges Bank acquired a new stake in Gilead Sciences in the 4th quarter valued at $2,617,152,000. 83.67% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research firms have issued reports on GILD. The Goldman Sachs Group increased their price target on Gilead Sciences from $125.00 to $130.00 and gave the stock a "neutral" rating in a report on Friday, April 17th. Morgan Stanley cut their price target on Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Wall Street Zen cut Gilead Sciences from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 9th. Oppenheimer increased their price target on Gilead Sciences from $128.00 to $165.00 and gave the stock an "outperform" rating in a report on Wednesday, February 11th. Finally, TD Cowen increased their price target on Gilead Sciences from $145.00 to $160.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $157.04.
Check Out Our Latest Stock Report on GILD
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
